Pharma Mar (XMAD:PHM) Tax Provision : €5.2 Mil (TTM As of Mar. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Pharma Mar Tax Provision?

Pharma Mar's tax provision for the three months ended in Mar. 2024 was €5.1 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2024 was €5.2 Mil.

Pharma Mar Tax Provision Historical Data

The historical data trend for Pharma Mar's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Mar Tax Provision Chart

Pharma Mar Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Tax Provision

Get a 7-Day Free Trial

12.47

-8.34

-2.27

5.57

4.76

Pharma Mar Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Tax Provision	Get a 7-Day Free Trial															4.63	0.53	-0.05	-0.35	5.07

Pharma Mar Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €5.2 Mil.

Pharma Mar (XMAD:PHM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Mar SA (XMAD:PHM) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

PHMMF:USA PHMe:UK 0RC6:UK

Address

Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770

Website

http://www.pharmamar.com

Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and market insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology, Diagnostics, Consumer chemicals, and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.